title: Nucleoside/nucleotide backbones for the treatment of HIV infection.
abstract: Nucleoside/nucleotide analogs (NAs) are essential components of most current antiretroviral regimens. Although many dual NA combinations may be used as backbones, not all display optimal results. For instance, some associations should be avoided due to antagonism (eg, zidovudine plus stavudine), high rates of toxicity (eg, didanosine plus stavudine) and/or increased risk of virological failure (eg, didanosine plus tenofovir). Moreover, the knowledge of plasma and intracellular interactions between different NAs is important for choosing appropriate combinations and optimal doses in order to optimize antiviral efficacy and minimize toxicities.
authors.affiliation: Service of Infectious Diseases and Service of Pharmacy, Hospital Carlos III, Madrid 28029, Spain.
authors.forename: Pablo
authors.initials: P
authors.lastname: Barreiro
authors.forename: Inmaculada
authors.initials: I
authors.lastname: Jiménez-Nácher
authors.forename: Benito
authors.initials: B
authors.lastname: García
authors.forename: Teresa
authors.initials: T
authors.lastname: García-Benayas
authors.forename: Pablo
authors.initials: P
authors.lastname: Rivas
authors.forename: Vincent
authors.initials: V
authors.lastname: Soriano
mesh_terms: D000818:Animals; D019380:Anti-HIV Agents / Q000737:chemistry* / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D009705:Nucleosides / Q000737:chemistry* / Q000627:therapeutic use*; D009711:Nucleotides / Q000737:chemistry* / Q000627:therapeutic use*
chemical_list: D019380:Anti-HIV Agents; D009705:Nucleosides; D009711:Nucleotides